Biora Therapeutics, Inc. (BIOR)
| Market Cap | 26.18M |
| Revenue (ttm) | 544,000 |
| Net Income (ttm) | -110.86M |
| Shares Out | 35.88M |
| EPS (ttm) | -5.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 219,984 |
| Open | 0.740 |
| Previous Close | 0.737 |
| Day's Range | 0.700 - 0.750 |
| 52-Week Range | 0.585 - 6.700 |
| Beta | 1.23 |
| Analysts | Strong Buy |
| Price Target | 15.00 (+1,955.64%) |
| Earnings Date | May 15, 2024 |
About BIOR
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora... [Read more]
Financial Performance
In 2023, BIOR's revenue was $4,000, a decrease of -98.69% compared to the previous year's $305,000. Losses were -$124.12 million, 225.3% more than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for BIOR stock is "Strong Buy" and the 12-month stock price forecast is $15.0.
News
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
Four device performance studies demonstrate the NaviCap platform's ability to deliver therapeutics directly to the colon under variable GI conditions.
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Dosing of all patients in clinical trial of BT-600 has been successfully completed, with results anticipated in late Q2 2024 Clinical data on device function of the NaviCap™ platform to be presented a...
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and ...
Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present clinical data on...
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
Dosing of all patients in the trial has been successfully completed Final results are expected to be available in late Q2 2024 SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (N...
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent relate...
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colon All NaviCap™ devices performed as intended and were well tolerated, with no saf...
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously annou...
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into definitive...
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial. Management to host conference call today at 4:30 PM ET.
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
SAN DIEGO, March 18, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results an...
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
Monetization of legacy asset brings in $3 million in nondilutive capital Convertible notes exchange brings in another $2.8 million in new capital and reduces Biora's net debt SAN DIEGO, March 11, 2024...
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
Data expected to be shared during March corporate update With SAD cohorts complete, MAD cohorts to begin dosing in March SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq:...
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
SAN DIEGO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will participate in the Inflamma...
Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.
SAN DIEGO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced participation in a virtual fireside ...
Biora Therapeutics Provides Outlook for 2024
Biora anticipates 2024 catalysts, including clinical study results for NaviCap™ platform and progress on pharma partnerships for BioJet™ platform.
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
First-in-human trial of BT-600 drug-device combination, following multiple successful device-only human studies SAD/MAD study to evaluate safety and PK/PD of BT-600, including concentrations in colon ...
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that its BioJet™ Systemic Oral Deliv...
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
SAN DIEGO, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it received an Issue Notificati...
Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors
Transaction results in nearly 60% reduction in net debt and brings $16 million in new capital; demonstrates investor confidence in near-term catalysts.
Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced a new research collaboration with a ...
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
BT-600 will deliver a proprietary liquid formulation of tofacitinib via the NaviCap™ device for topical delivery to the colon SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nas...
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
NaviCap™ Targeted Oral Delivery platform advancing toward initiation of phase 1 clinical trial by year end Pharma collaborations accelerate for the BioJet™ Systemic Oral Delivery platform, which shows...
Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update
Biora will report financial results and provide a corporate update for the third quarter on on Monday, November 13, 2023, at 4:30 PM EST / 1:30 PM PST
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biora Therapeutics, Inc. - BIOR
NEW YORK , Nov. 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biora Therapeutics, Inc. ("Biora" or the "Company") (NASDAQ: BIOR). Such investors are advised t...